MELTZER LESLIE 4

What Happened
Leslie Meltzer, Chief Research and Development at Apellis Pharmaceuticals (APLS), received a grant of 45,220 restricted stock units (RSUs) on January 28, 2026. The Form 4 reports an acquisition price of $0.00 (typical for RSU awards); the filing does not state a dollar value. This was an equity award (compensation), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-01-28; Form 4 filed 2026-01-30 (appears timely within the 2-business-day window).
• Security and amount: 45,220 Restricted Stock Units (code A: award/grant). Reported acquisition price: $0.00.
• Vesting: Footnote F1 — RSUs vest 25% annually over four years from the grant date, subject to continued service.
• Shares owned after transaction: not stated in the filing.
• No indication of a 10b5-1 plan, sale, exercise, or tax-withholding event in this filing.

Context
RSUs are a form of equity compensation that convert into shares as they vest; the Form 4 records the grant, not an immediate market transaction. The economic value of the award equals the company share price when RSUs vest (not shown on this Form 4). Awards like this are common for executive compensation and are not, by themselves, a direct buy or sell signal.